Tudor Investment Corp ET AL Purchases New Holdings in Envista Holdings Corporation $NVST
Tudor Investment Corp ET AL has acquired a new position of 81,686 shares in Envista Holdings Corporation (NYSE:NVST), valued at approximately $1.664 million, as per its recent SEC disclosure. Envista recently beat quarterly earnings expectations with $0.38 EPS against a $0.32 consensus and reported a 15% year-over-year revenue increase. The company has also set its FY2026 EPS guidance between $1.350 and $1.450.
Vanguard disaggregates holdings; reports 0 Envista shares (NVST)
The Vanguard Group filed an amended Schedule 13G, reporting 0 shares of Envista Holdings Corp common stock following an internal realignment. This change means certain Vanguard subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538. The filing clarifies that this is a reporting re-allocation, not an actual sale or change in economic ownership of Envista shares by underlying funds.
Envista Holdings Corp (0HV.DE) Fundamental Analysis
Envista Holdings Corp (0HV.DE) exhibits weak financial fundamentals, receiving a Fundamental Health Score of 26.2/100 due to low profitability, weak growth trends, and a high PE ratio. Despite some balanced valuation metrics and a strong balance sheet, the company struggles with efficiency, reflected in its ROE, operating margin, and negative revenue growth. Its performance lags behind sector averages in most key metrics, though it shows strong liquidity.
Envista Holdings Corp (NVST) Shares Down 3.09% on Mar 18
Envista Holdings Corp (NVST) shares dropped 3.09% on March 18, closing at $25.25. While this is 17.01% below its 52-week high, it remains 77.53% above its 52-week low. Wall Street analysts forecast an average target price of $28.91 for NVST, indicating a potential 14.51% upside, with a consensus "Outperform" rating from brokerage firms.
A Look At Envista Holdings (NVST) Valuation After Recent Share Price Volatility
Envista Holdings (NVST) has seen recent share price volatility, with a 14% decline over the past month but a 14% total return over the last three months. The company is considered 12.1% undervalued with a fair value of $28.46, driven by increasing R&D and successful product launches in digital dentistry. However, its current P/E ratio of 87.2x is significantly higher than the industry average, suggesting potential valuation risk.
Best Value Stocks to Buy for March 16th
The article highlights three value stocks for investors to consider on March 16th: OptimizeRx Corporation (OPRX), Envista Holdings Corporation (NVST), and Strattec Security Corporation (STRT). All three companies hold a Zacks Rank #1 and exhibit strong value characteristics, including favorable price-to-earnings ratios compared to their respective industries and positive revisions in earnings estimates. The analysis suggests these stocks offer potential for investors seeking undervalued growth opportunities.
Has Envista Holdings (NVST) Pulled Back Too Far After Recent Share Price Weakness?
This article analyzes whether Envista Holdings (NVST) is currently undervalued after recent share price weakness. Using a Discounted Cash Flow (DCF) analysis, the stock appears undervalued by 14.8%, while a Price-to-Earnings (P/E) ratio comparison suggests it's overvalued compared to industry averages and its proprietary "Fair Ratio." The article also presents bullish and bearish narratives for NVST, with fair value estimates ranging from US$28.46 to US$20.03 per share, encouraging investors to compare these assumptions with their own views.
Here's Why Envista (NVST) Is a Great 'Buy the Bottom' Stock Now
Envista (NVST) stock has recently seen bearish trends but a hammer chart pattern suggests a potential reversal, indicating that bulls might be gaining control. This technical signal is supported by strong fundamental indicators, including an upward trend in earnings estimates and a Zacks Rank #1 (Strong Buy), pointing to improved prospects for the company. Investors are encouraged to consider NVST as a "buy the bottom" opportunity given these reinforcing technical and fundamental factors.
Envista, Baxter, Artivion, Dentsply Sirona, and Cigna Stocks Trade Down, What You Need To Know
Several healthcare and dental companies, including Envista, Baxter, Artivion, Dentsply Sirona, and Cigna, saw their stock prices fall after a February jobs report indicated an unexpected contraction in employment and significant job losses in the healthcare sector. This data has raised concerns among investors about a potential economic slowdown and decreased healthcare spending. Dentsply Sirona, in particular, experienced a 4.1% drop despite a recent 13.4% gain a week prior due to a revenue beat, though its full-year guidance was disappointing.
First Eagle Investment Management LLC Acquires New Shares in Envista Holdings Corporation $NVST
First Eagle Investment Management LLC has acquired 212,500 new shares in Envista Holdings Corporation (NYSE:NVST) during the third quarter, valued at approximately $4.33 million, representing a 0.13% stake. This comes as Envista reported strong quarterly earnings, surpassing analyst estimates, and provided positive FY26 guidance for EPS. Wall Street analysts currently rate Envista with a "Moderate Buy" consensus.
NVST Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Envista Holdings Corp (NVST), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's financial health signals such as profitability, growth, leverage, liquidity, cash flow, and returns, alongside detailed metrics like revenue, EBITDA, net income, and EPS. The analysis also includes Altman Z-Score, Piotroski F-Score, earnings quality, and interest coverage to assess financial stability and potential risks.
Envista Holdings Corp. Experiences Valuation Adjustment Amid Strong Market Performance
Envista Holdings Corp., a small-cap pharmaceuticals and biotechnology company, has seen a valuation adjustment, with its stock trading at $29.30. The company exhibits strong year-to-date performance, outperforming the S&P 500 with a 34.96% return compared to the S&P 500's 0.94%. Key financial metrics include a P/E ratio of 52 and a price-to-book value of 1.07.
NVST SEC Filings - Envista Holdings Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Envista Holdings Corp (NVST) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading reports. It details recent filings such as an insider sale by an SVP, a proposed sale of restricted stock, and reports of beneficial ownership by investment firms like Harris Associates and Franklin Mutual Advisers. The platform also offers AI-powered summaries to help users understand key points and implications of these regulatory documents.
Envista (NYSE: NVST) awards equity grants to General Counsel Nance
Envista Holdings Corp. (NYSE: NVST) granted its General Counsel, Mark E. Nance, various equity awards on February 25, 2026, including 23,070 Performance Share Units, 30,040 stock options, and 12,675 Restricted Stock Units (RSUs). These awards have multi-year vesting schedules tied to performance and continued service. Additionally, 3,368 shares were withheld to cover tax obligations related to RSU vesting.
Vanguard Group Inc. Sells 591,982 Shares of Envista Holdings Corporation $NVST
Vanguard Group Inc. reduced its stake in Envista Holdings Corporation (NYSE:NVST) by 3.5% in the third quarter, selling 591,982 shares, but still holds 16,383,708 shares valued at approximately $333.7 million. Envista reported strong quarterly earnings of $0.38 EPS, beating estimates, with revenue up 15% year-over-year, and provided positive FY2026 guidance. The company's stock currently trades around $29.22, and analysts have a consensus "Moderate Buy" rating with an average target price of $27.08.
Envista (NVST) President awarded PSUs, RSUs, options in Form 4 filing
Envista Holdings Corp's President of Diagnostics, Robert Befidi, was granted 13,845 Performance Share Units, 18,020 employee stock options, and 7,605 restricted stock units, as detailed in a recent Form 4 SEC filing. These equity awards are subject to vesting schedules, with PSUs based on three-year performance and stock options and RSUs vesting ratably over three years. Additionally, 2,177 common shares were withheld to cover tax obligations related to vesting RSUs, leaving Befidi with 50,932 directly owned common shares.
Envista (NYSE: NVST) executive granted PSUs, RSUs, options and tax-share withholding
Envista Holdings Corp (NYSE: NVST) executive Veronica Acurio, President of Orthodontics, received grants of 13,845 Performance Share Units, 18,020 stock options, and 7,605 Restricted Stock Units. The filing also indicated a disposition of 1,412 common shares at $29.59 each to cover tax withholding obligations. Following these transactions, Ms. Acurio directly holds 56,516 shares of Envista common stock.
Envista (NYSE: NVST) grants stock, options and RSUs to executive
Envista Holdings Corp (NYSE: NVST) executive Stefan Nilsson, President of Nobel Biocare, was granted 13,845 Performance Share Units, an option for 18,020 shares, and 7,605 Restricted Stock Units (RSUs) on February 25, 2026. These equity awards vest over three years and are subject to continued service and performance measures. Additionally, 182 common shares were withheld and sold to cover tax obligations related to RSU vesting.
NVST PE Ratio & Valuation, Is NVST Overvalued
Envista Holdings Corp (NVST) is currently categorized as "Undervalued" based on its forward PE ratio of 17.64 compared to its five-year average of 20.21. The article calculates NVST's fair price to be between $30.92 and $41.84, suggesting it is undervalued by 5.53% relative to its current price of $29.21. Despite exhibiting a P/S ratio significantly above the industry average, the company shows robust revenue growth.
Envista (NVST) CEO awarded PSUs, options and RSUs while shares withheld for taxes
Envista Holdings Corp CEO Paul A. Keel reported new equity awards including 132,885 Performance Share Units, 115,320 stock options, and 48,670 Restricted Stock Units, all vesting over three years subject to continued service and performance goals. To cover tax withholding on vested RSUs, 11,840 shares were withheld at $29.59 per share. Following these transactions, Keel directly owns 384,385 common shares of Envista.
Envista (NYSE: NVST) SVP awarded stock units, options and tax-withheld shares
Envista Holdings Corp SVP Mischa Reis reported mixed equity compensation activity, including the receipt of 10,770 Performance Share Units, 14,020 stock options, and 5,915 restricted stock units. Additionally, 2,976 shares of common stock were withheld to cover tax obligations related to previously vested RSUs, valued at $29.59 per share. Following these transactions, Reis directly owns 35,321 shares of Envista common stock.
Envista (NVST) CAO reports RSU grant and tax-wIthholding share disposition
Envista Holdings Corp's Chief Accounting Officer, Faez C. Kaabi, reported an acquisition of 13,520 Restricted Stock Units (RSUs) which will vest over three years. Concurrently, 4,964 shares were disposed of at $29.59 each to cover tax withholding obligations related to previously vested RSUs. Following these transactions, Kaabi directly holds 58,552 shares of Envista common stock.
3 Reasons to Avoid NVST and 1 Stock to Buy Instead
This article advises investors to avoid Envista Holdings Corp (NVST) despite its recent stock performance. The author highlights three main reasons: disappointing long-term revenue growth, previous growth initiatives losing money due to negative ROIC, and a decline in new investment returns. Instead, the article suggests looking into the most entrenched endpoint security platform on the market and provides a link to "Top 6 Stocks" list.
Envista Stock Rises Post Q4 Earnings & Revenue Beat, Gross Margin Down
Envista Holdings Corporation (NVST) reported strong Q4 2025 results, with adjusted EPS up 58.3% year over year and revenues increasing by 15%, both beating Zacks Consensus Estimates. Despite a contraction in gross margin, the company's operational profit significantly improved, and its shares rallied post-announcement. Envista remains optimistic about its core sales growth and adjusted EBITDA margins for 2026, benefiting from its diverse portfolio in specialty products and technologies.
5 Must-Read Analyst Questions From Envista's Q4 Earnings Call
Envista Holdings (NVST) reported stronger-than-anticipated Q4 results with significant revenue and profit growth, driven by new product launches and increased customer training. This article highlights five key analyst questions from the earnings call, covering topics such as 2026 guidance risks and upsides, drivers for Q4 growth, new product contributions to implant growth, Spark's profitability, and SG&A leverage and R&D investment. The company's future catalysts include new product commercial impact, Spark's operational efficiency, and developments in China's VBP policy.
Insider Selling: Envista (NYSE:NVST) SVP Sells 9,675 Shares of Stock
Envista Holdings Corporation's SVP, Mischa Reis, sold 9,675 shares of company stock for approximately $290,250 on February 10th, reducing their holdings by 23%. This insider sale comes as Envista's stock trades near its 52-week high with a high P/E ratio, despite strong Q4 earnings, positive guidance, and analyst upgrades. Investors are advised to consider this insider activity alongside the company's performance and valuation.
Mizuho raises Envista Holdings stock price target to $27 on strong outlook
Mizuho has increased its price target for Envista Holdings Corp. (NYSE:NVST) to $27.00 from $24.00, maintaining a Neutral rating, following the company's better-than-expected 2026 guidance. Envista's stock is currently trading near its 52-week high, boasting a 35.24% year-to-date return. The revised target is based on an increased 2026 and 2027 EPS forecast, with Mizuho anticipating Envista will outgrow the dental market.
Mizuho raises Envista Holdings stock price target to $27 on strong outlook
Mizuho has increased its price target for Envista Holdings Corp. to $27 from $24, maintaining a Neutral rating, following the company's strong 2026 guidance that met or exceeded medium-term targets. Envista is also expected to outgrow the dental market in 2026 and has seen upward revisions in its 2026 and 2027 EPS estimates, despite its current high P/E ratio. The stock is considered slightly undervalued by InvestingPro's Fair Value assessment.
William Blair upgrades Envista Holdings stock rating to Outperform
William Blair upgraded Envista Holdings (NYSE: NVST) from Market Perform to Outperform following strong Q4 2025 results that exceeded expectations. The firm cited Envista's projected mid-single-digit growth, double-digit EPS growth expectations for 2026, and strategic investments in implants and new products as reasons for the upgrade, despite current high P/E ratios. InvestingPro data also shows Envista's strong financial health with a Piotroski Score of 9.
Surging Earnings Estimates Signal Upside for Envista (NVST) Stock
Envista (NVST) is showing a strong earnings outlook, with analysts consistently raising their estimates for the dental products maker, leading to a Zacks Rank #1 (Strong Buy). This optimistic trend in earnings estimate revisions typically correlates with near-term stock price movements, and Envista has already seen a 23.2% increase in its stock over the past four weeks. The company is projected to achieve significant year-over-year earnings growth for both the current quarter and the full year, indicating potential for continued upside.
Envista Holdings Corp (NYSE:NVST) Q4 2025 Earnings Call Transcript
Envista Holdings Corp (NYSE:NVST) reported strong Q4 and full-year 2025 results, with core growth, EBITDA, and EPS exceeding medium-term objectives from their value creation plan. The company achieved widespread growth across all businesses, improved operational efficiency, and significantly increased shareholder returns through a share repurchase program. For 2026, Envista projects continued progress with core revenue growth of 2% to 4% and enhanced profitability, while acknowledging potential market volatility and specific VBP impacts in China.
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)
The article highlights bullish sentiments from financial analysts on three healthcare stocks: Cigna (CI), Envista Holdings (NVST), and Arrowhead Pharmaceuticals (ARWR). Cigna received a Buy rating from Guggenheim and RBC Capital with price targets suggesting an 18.8% upside. Envista Holdings was reiterated a Buy by Bank of America Securities and upgraded to Buy by Leerink Partners, with a moderate buy consensus. Arrowhead Pharmaceuticals also maintained a Buy rating from RBC Capital and B. Riley Securities, projecting a significant upside.
Envista (NVST) Climbs 23% on Swing to Profit
Envista Holdings Corp. (NYSE:NVST) saw its stock climb by 23.4% to a nearly three-year high after reporting a significant swing to profitability. The company posted a $47 million net income in the last year, reversing a $1.1 billion net loss from 2024, with sales increasing by 8% to $2.7 billion. For the current year, Envista projects 2 to 4 percent core sales growth and a 7 to 13 percent increase in adjusted EBITDA.
Envista (NVST) Climbs 23% on Swing to Profit
Envista Holdings Corp. (NYSE:NVST) saw its stock climb 23.4% last week, reaching a nearly three-year high, after the company reported a swing to profitability in the previous year. The dental equipment company posted a net income of $47 million for last year, a significant improvement from a $1.1 billion net loss in 2024. Envista expects core sales to grow by 2 to 4 percent and adjusted EBITDA to increase by 7 to 13 percent for the current year.
William Blair upgrades Envista Holdings stock rating to Outperform By Investing.com
William Blair has upgraded Envista Holdings Corp. (NYSE:NVST) from Market Perform to Outperform due to strong quarterly results that surpassed expectations in sales and EPS. The dental products company, currently trading near its 52-week high, shows exceptional financial strength with a perfect Piotroski Score of 9. Despite a high P/E ratio, William Blair anticipates continued momentum driven by investments in implants and new product launches, projecting potential upside from EPS growth.
William Blair upgrades Envista Holdings stock rating to Outperform By Investing.com
William Blair has upgraded Envista Holdings (NYSE:NVST) from Market Perform to Outperform, citing strong quarterly results that exceeded expectations and a belief that the company's projected mid-single-digit growth and double-digit EPS growth in 2026 justify a premium valuation. Despite a high P/E ratio, InvestingPro analysis suggests the stock may be undervalued, with key growth drivers identified in implants and new product launches. The upgrade follows Envista's impressive Q4 2025 earnings and optimistic 2026 guidance, though Needham maintained a Hold rating.
Piper Sandler raises Envista Holdings stock price target to $25 on strong Q4
Piper Sandler has increased its price target for Envista Holdings Corp. to $25 from $21, maintaining a neutral rating, following the company's strong fourth-quarter performance with revenues and adjusted EPS exceeding Wall Street expectations. While the stock has already surpassed this new target, trading near its 52-week high, Piper Sandler expressed some reservation about the 2026 guidance, noting that the valuation appears full and future performance will likely depend on broader, albeit sluggish, dental market conditions. William Blair upgraded Envista to Outperform, citing strong results that even after adjusting for temporary benefits, remained significantly above consensus.
NVST Q4 Deep Dive: Broad-Based Growth and Margins Lift Outlook for 2026
Envista Holdings (NVST) reported strong Q4 CY2025 results, exceeding revenue and profit expectations with sales up 15% year-on-year to $750.6 million and adjusted EPS of $0.38, beating analyst consensus. The company's performance was driven by broad-based growth across all business units, new product launches, expanded clinical training, and operational improvements, including reduced general and administrative expenses. Envista's outlook for 2026 is positive, with guidance for sustained investment in R&D, new product innovation, and continued focus on profitability, despite potential macroeconomic volatility and uncertainties in the China market.
Envista Holdings stock hits 52-week high at $27.72
Envista Holdings (NVST) stock has reached a new 52-week high of $27.72, marking a 95% increase from its 52-week low. This surge is attributed to investor confidence, strategic initiatives, robust financial health, and strong fourth-quarter 2025 financial results that surpassed analyst expectations. While William Blair upgraded its rating to Outperform, Needham maintained a Hold rating despite the positive performance.
Why Envista (NVST) Stock Is Trading Up Today
Shares of Envista Holdings (NVST) jumped 13.5% after the company reported better-than-expected fourth-quarter financial results, with both revenue and adjusted earnings surpassing Wall Street estimates. The dental products maker also provided an optimistic full-year earnings outlook that exceeded projections, contributing to investor confidence. The stock saw a new 52-week high, up 31.6% since the beginning of the year.
Piper Sandler raises Envista Holdings stock price target to $25 on strong Q4
Piper Sandler has increased its price target for Envista Holdings Corp. (NYSE:NVST) to $25.00 from $21.00, maintaining a neutral rating, following the dental products company's strong fourth-quarter performance. Envista's revenue and adjusted EPS significantly surpassed Wall Street expectations, driven by double-digit growth in both segments. Despite the stock already trading above the new target, Piper Sandler expressed some reservation about the company's 2026 guidance, noting a "sluggish but stable" dental market.
Needham maintains Hold rating on Envista stock despite strong Q4 results
Needham has reiterated its Hold rating on Envista Holdings Corp. (NYSE:NVST) despite the company reporting strong fourth-quarter 2025 financial results that exceeded analyst expectations. The company showed financial strength with a high P/E ratio, strong revenue growth, and positive guidance for 2026. However, Needham believes the near-term upside is already priced in due to a significant increase in share price during after-hours trading.
William Blair upgrades Envista Holdings stock rating to Outperform
William Blair has upgraded Envista Holdings Corp. (NYSE:NVST) from Market Perform to Outperform following strong quarterly results that exceeded market expectations and a perfect Piotroski Score of 9. The firm projects mid-single-digit growth and double-digit EPS growth in 2026, driven by investments in implants and new product launches, despite previous valuation concerns. Envista’s recent financial performance and positive outlook led to the upgrade, with expectations for continued momentum and potential upside.
Envista: Q4 Earnings Snapshot
Envista Holdings Corp. (NVST) reported strong fourth-quarter earnings, surpassing Wall Street expectations with a profit of 38 cents per share, adjusted for special costs, and revenue of $750.6 million. For the full year, the company had a profit of 28 cents per share on revenue of $2.72 billion. Envista also provided a positive outlook, forecasting full-year earnings in the range of $1.35 to $1.45 per share.
Envista (NVST) Tops Q4 Earnings and Revenue Estimates
Envista (NVST) exceeded Q4 earnings and revenue estimates, reporting $0.38 per share against an expected $0.32, and revenues of $750.6 million, surpassing the consensus by 11.16%. The company has consistently beaten EPS and revenue estimates over the past four quarters. Envista currently holds a Zacks Rank #2 (Buy), indicating potential outperformance in the near future, although the Medical - Products industry outlook is in the bottom 29%.
Earnings call transcript: Envista Holdings Q4 2025 beats expectations
Envista Holdings (NVST) reported strong Q4 2025 results, exceeding analyst expectations with an EPS of $0.38 and revenues of $751 million. The company's core sales grew by 10.8%, driven by new product introductions and increased clinical training. Envista provided a positive outlook for 2026, projecting core sales growth of 2-4% and adjusted EPS between $1.35 and $1.45, underpinned by a solid value creation plan and continued investment in R&D.
Envista: Q4 Earnings Snapshot
Envista Holdings Corp. reported strong financial results for the fourth quarter, with net income of $32.9 million and adjusted earnings of 38 cents per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $750.6 million for the quarter, and provided an outlook for full-year earnings between $1.35 and $1.45 per share.
Envista: Fourth Quarter Earnings Overview
Envista Holdings Corp. reported strong fourth-quarter results, with a net income of $32.9 million ($0.20 per share) and adjusted earnings of $0.38 per share, surpassing analyst expectations. The dental products manufacturer generated $750.6 million in revenue for the quarter, also exceeding estimates. For the full year, Envista reported $47 million in profit and $2.72 billion in revenue, projecting full-year earnings between $1.35 and $1.45 per share.
Envista Holdings soars after beating Q4 estimates, issues strong guidance
Envista Holdings Corporation (NYSE:NVST) surpassed Q4 analyst expectations with adjusted EPS of $0.38 and revenue of $751 million, leading to an 11.6% jump in after-hours trading. The dental products company also provided strong guidance for fiscal year 2026, projecting adjusted EPS of $1.35 to $1.45. This strong performance was attributed to growth across all major businesses and geographical regions, alongside significant share repurchases.
Envista (NYSE:NVST) Beats Expectations in Strong Q4 CY2025
Envista Holdings (NYSE:NVST) significantly surpassed Wall Street's expectations in Q4 CY2025, reporting a 15% year-on-year revenue increase to $750.6 million and a non-GAAP profit of $0.38 per share, beating estimates by 17.7%. The company also provided strong adjusted EPS guidance for CY2026, exceeding analyst projections. While long-term revenue growth has been moderate, and operating margins have historically struggled, the latest quarter shows promising improvements in profitability and efficiency, leading to a positive market reaction.
